Management of prostate cancer. Part 3: Metastatic disease

Expert Review of Anticancer Therapy

Volumn 6, Issue 5, 2006, Pages 813-821

  Shah, Jyoti ^a   Khaksar, Sara Jane ^b   Sooriakumaran, Prasanna ^b  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

Androgen deprivation; Bisphosphonates; Chemotherapy; Hormone refractory; Metastatic prostate cancer; Novel agents; Radiopharmaceuticals

Indexed keywords

ABARELIX; ACETYLSALICYLIC ACID; AMINOGLUTETHIMIDE; ANDROGEN; ANTACID AGENT; ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; DIETHYLSTILBESTROL; DOCETAXEL; ESTRAMUSTINE; ESTROGEN; ETOPOSIDE; FLUTAMIDE; GLUCOCORTICOID; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; KETOCONAZOLE; MITOXANTRONE; PLACEBO; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; PROTON PUMP INHIBITOR; RADIOPHARMACEUTICAL AGENT; SAMARIUM 153; STRONTIUM 89; UNINDEXED DRUG; ZOLEDRONIC ACID; ANGIOGENESIS INHIBITOR;

ANALGESIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PAIN; CANCER SURVIVAL; CARCINOGENESIS; CARDIOVASCULAR RISK; CARDIOVASCULAR SYMPTOM; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; EARLY DIAGNOSIS; ERECTILE DYSFUNCTION; FATIGUE; FLU LIKE SYNDROME; FRACTURE; GASTROINTESTINAL TOXICITY; GYNECOMASTIA; HEART INFARCTION; HORMONE DEFICIENCY; HORMONE INHIBITION; HOT FLUSH; HUMAN; HYPOCALCEMIA; LIBIDO DISORDER; LIVER TOXICITY; LOW DRUG DOSE; LUNG EMBOLISM; MALE; META ANALYSIS; METASTASIS POTENTIAL; MULTIMODALITY CANCER THERAPY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; ORCHIECTOMY; OSTEOLYSIS; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION; VENOUS THROMBOEMBOLISM; DRUG RESISTANCE; IMMUNOTHERAPY; METASTASIS; PHYSIOLOGY; PROSTATE TUMOR; SURVIVAL;

ANDROGEN ANTAGONISTS; ANDROGENS; ANGIOGENESIS INHIBITORS; DIPHOSPHONATES; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SURVIVAL ANALYSIS;

EID: 33745131467     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.5.813     Document Type: Review

References (65)

1. Ornstein D, Beiser J, Andriole G. Anaemia in men receiving combined finasteride and fluatmide therapy for advanced prostate cancer. BJU Int. 83, 43-46 (1999).
2. Fonseca R, Rajkumar S, White W, Tefferi A, Hoagland H. Anaemia after orchiectomy. Am. J. Hematol. 59, 230-233 (1998).
3. Strum S, McDermed J, Scholz M, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormonal blockade. BJU Int. 79, 933-941 (1997).
4. Reynard J, Peters T, Gillatt D. Prostate-specific antigen and prognosis in patients with metastatic prostate cancer: a multivariate analysis of prostate cancer mortality. BJU Int. 75, 507-515 (1995).
5. Smith J, Lange P, Janknegt R, Abbou C, deGery A. Serum marker as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. J. Urol. 157, 1329-1334 (1997).
6. Kelly W, Scher H, Mazumdar M, Vlamis V, Scwartz M, Fossa S. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 11, 607-615 (1993).
7. Miller J, Ahman F, Drach G, Emerson S, Bottaccini M. The clinical usefulness of serum PSA after hormonal therapy for metastatic carcinoma of the prostate. J. Urol. 147, 956-961 (1992).
8. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. 337, 295-300 (1997).
9. Greenspan S, Coates P, Sereika S, Nelson J, Trump D, Resnick N. Bone loss after initiation of androgen therapy in patients with prostate cancer. J. Clin. Endocrinol. Metab. 90, 6410-6417 (2005).
10. Immediate versus deferred treatment for advanced prostate cancer: initial results of the Medical Research Council trial. Br. J. Urol. 79, 235-246 (1997).
11. Sticker H. Luteinizing hormone-releasing hormone antagonist in prostate cancer. Urology 58, 24-27 (2001).
12. Goldenberg S, Bruchovsky N, Gleave M, Sullivan L, Akakura K. Intermittent androgen suppression treatment of prostate cancer: a preliminary report. Urology 45, 839-844 (1995).
13. Eisenberger M, Blumenstein B, Crawford E et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. 339, 1036-1042 (1998).
14. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 355(9214), 1491-1498 (2000).
15. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomized trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group. Lancet 346, 265-269 (1995).
16. Taplin M, Bubley G, Ko Y. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 59, 149-153 (1999).
17. Kelly W, Scher H. Prostate specific antigen decline after anti-androgen withdrawal: the flutamide withdrawal syndrome. J. Urol. 49, 607-609 (1993).
18. Small E, Schelhammer P, Venner P. A double-blind assessment of antiandrogen withdrawal from casodex (C) or eulexin (E) therapy while continuing luteinizing hormone releasing hormone analogue (LHRL-A) therapy for patients with stage D2 prostate cancer. Proc. Am. Soc. Clin. Oncol. 15, 255 (1996).
19. Pienta K, Redman B, Bandekar R et al. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 50, 401-406 (1997).
20. Smith D, Redman B, Flaherty L, Li L, Strawderman M, Pieta K. A phase II trial of oral diethylstilbestrol as a second line hormonal agent in advanced prostate cancer. Urology 52, 257-260 (1998).
21. Dawson N. Treatment of progressive metastatic prostate cancer. Oncology 7, 7-24 (1993).
22. Fuse H, Nozaki T, Fujiuchi Y, Nagakawa O, Okumwa A. Treatment with prednisolone of hormone refractory prostate cancer. Arch. Androl. 52, 35-38 (2006).
23. Benson R, Hasa S, Jones A. External beam radiotherapy for palliation of multiple sites of pain from metastatic carcinoma of the prostate. J. Urol. 127, 69-71 (1981).
24. Nielsen OS, Bentzen SM, Sandberg E, Gadeberg CC, Timothy AR. Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother. Oncol. 47(3), 233-240 (1998).
25. Hartsell WF, Scott CB, Bruner DW et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J. Natl Cancer Inst. 97(11), 798-804 (2005).
26. Aaron A. Treatment of metastatic adenocarcinoma of the pelvis and extremities. Am. J. Bone Joint Surg. 79, 917-931 (1997).
27. Ben-Josef E, Porter A. Radioisotopes in prostate carcinoma. Ann. Med. 29, 31-35 (1997).
28. Porter A, McEwan A, Powe J et al. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field irradiation in the management of endocrine resistant metastatic prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 25, 805-813 (1993).
29. 89 chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur. Urol. 44(5), 519-526 (2003).
30. Sartor O, Reid R, Hoskin P et al. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63, 940-945 (2004).
31. Saad F, Gleason G, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J. Natl Cancer Inst. 94, 1458-1468 (2002).
32. Tannock I, Wit R, Berry W et al. For the TAX 327 investigators. Docetaxol plus prednisolone or mitoxantrone plus prednisolone for advanced prostate cancer. N. Engl. J. Med. 351, 1502-1512 (2004).
33. Petrylak D, Tangen C, Hussain M. Docetaxol and estramustine compared with mitoxantrone and prednisolone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513-1520 (2004).
34. Tannock I, Osoba D, Stockler M et al. Chemotherapy with mitoxantrone plus prednisolone or prednisolone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14, 1756-1764 (1996).
35. Blumenstein B, Crawford ED, Saiers JH, Stephens RL, Rivkin SE, Coltman CA Jr. Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study. J. Urol. 150(2 Pt 1), 411-413 (1993).
36. Laurie JA, Hahn RG, Therneau TM et al. Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. Cancer 69(6), 1440-1444 (1992).
37. Casey M, Byrd W, Macdonald P. Massive amounts of immunoreactive endothelin in human seminal fluid. J. Clin. Endocrinol. Metab. 74, 223-225 (1992).
38. Nelson J, Hedican S, George D et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1, 944-999 (1995).
39. 2+ from extra- and intracellular pools in osteoblastic cells. Am. J. Physiol. 257, 797-803 (1989).
40. Yin J, Mohammad K, Kakonen S et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl Acad. Sci. USA 100, 10954-10959 (2003).
41. Carducci M, Nelson J, Bowling M et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J. Clin. Oncol. 20, 2171-2180 (2002).
42. Trump D, Hershberger P, Bernadi R et al. Antitumor activity of calcitriol: pre-clinical and clinical studies. J. Steroid Biochem. Mol. Biol. 89, 519-526 (2004).
43. Beer T, Eilers K, Garzotto M, Egorin M, Lowe B, Henner W. Weekly high-dose calcitriol and docetaxol in metastatic androgen-independent prostate cancer. J. Clin. Oncol. 21, 123-128 (2003).
44. Bauer K, Dixon S, Figg W. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem. Pharmacol. 55, 1827-1834 (1998).
45. Figg W, Dahut W, Duray P et al. A randomized phase II trial of thalidomide, an antiangiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res. 7, 1888-1893 (2001).
46. Dahut W, Gulley J, Arlen P et al. Randomized phase II trial of docetaxol plus thalidomide in androgen-independent prostate cancer. J. Clin. Oncol. 22, 2532-2539 (2004).
47. Horne M, Figg W ,Arlen P et al. Increased frequency of venous thromboembolism with the combination of docetaxol and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy 23, 315-318 (2003).
48. Sternberg C, Whelan P, Hetherington J et al. Phase III trial of satraplatin, an oral platinum plus prednisolone vs. prednisolone alone in patients with hormone-refractory prostate cancer. Oncology 68, 2-9 (2005).
49. Hussain T, Tangen C, Lara P, Vaishampayan U et al. Ixabepilone is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a SouthWest Oncolgy Group trial S0111. J. Clin. Oncol. 23, 8724-8729 (2005).
50. Eaton J, Perry M, Nicholson S et al. Allogenic whole-cell vaccine: a phase I/II study in men with hormone refractory prostate cancer. BJU Int. 89, 19-26 (2002).
51. Small E, Fratesi P, Resse D. Immunotherapy of hormone-refractory prostate cancer with antigen loaded dendritic cells. J. Clin. Oncol. 18, 3894-3903 (2000).
52. Steiner M. Review of peptide growth factors in benign prostatic hyperplasia and urological malignancies. J. Urol. 153, 1085-1096 (1995).
53. Blades R, Keating P, McWilliam L, George N, Stern P. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 46, 681-686 (1995).
54. Healy C, Simons J, Carducci M et al. Impaired expression and function of signal-transducing ζ-chains in peripheral T cells and natural killer cells in pateints with prostate cancer. Cytometry 32, 109-119 (1998).
55. Liu H, Rajasekaran A, Moy P et al. Constitutive and antibody-induced internalization of prostate-specific antigen. Cancer Res. 58, 4055-4060 (1998).
56. Milowsky M, Nanus D, Kostakoglu L, Vallabhajosula S, Goldsmith S, Bander N. Phase I trial of yttrium-90-labelled, antiprostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J. Clin. Oncol. 22, 2522-2531 (2004).
57. Dawson N, Cooper M, Figg W et al. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 76, 453-462 (1995).
58. Kelly W, Curley T, Leibertz C, Dnistrian A, Schwartz M, Scher H. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J. Clin. Oncol. 15, 2208-2213 (1995).
59. Ziada A, Bargawi A, Glode L et al. The use of transtuzumab in the treatment of hormone refractory prostate cancer: phase II trial. Prostate 61, 332-337 (2004).
60. Hueman M, Dehqanzada Z, Novak T et al. Phase I clinical trial of a HER-2/ neu peptide (E75) vaccine for the prevention of prostate-specific recurrence in high-risk prostate cancer patients. Clin. Cancer Res. 11, 7470-7479 (2005).
61. Lorusso P. Phase I studies of ZD1839 in patients with common solid tumours. Semin. Oncol. 30, 21-29 (2003).
62. Tiffany N, Wersinger E, Garzotto M, Beer T. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology 63, 934-939 (2004).
63. Ye D, Mendelsohn J, Fan Z. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA Pca 2a and MDA Pca 2b prostate cancer cells. Clin. Cancer Res. 5, 2171-2177 (1999).
64. Trump D, Canil CM, Moore MJ et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. Urol. Oncol. 23, 378-379 (2005).
65. Festuccia C, Gravina G, Angelucci A et al. Additive antitumour effects of the epidermal growth factor receptor tyrosine kinase inhibiotr, gefitinib (Iressa) and the nonsteroidal antiandrogen, bicalutamide (Casodex) in prostate cancer cells in vitro. Int. J. Cancer 115, 630-640 (2005).